Delays in COVID-19 Diagnosis and Hospitalization and Outcomes — New York City, New

2 York, USA, October 2020–November 2021

- 3 Laura E. Graf *, MPH, Eric R. Peterson, MPH, Jennifer Baumgartner, MSPH, Anne Fine, MD, 1
- 4 Corinne N. Thompson, PhD, ² Kathleen Blaney, MPH, RN, Sharon K. Greene, PhD, MPH
- 5 Author affiliations: New York City Department of Health and Mental Hygiene, Queens, New
- 6 York, USA (L.E. Graf, E.R. Peterson, J. Baumgartner, A. Fine, C.N. Thompson, K. Blaney, S.K.
- 7 Greene)

11

1

- 8 ¹Current affiliation: Council of State and Territorial Epidemiologists, Atlanta, Georgia, USA
- 9 ²Current affiliation: NYU Langone Health, New York, New York, USA
- 10 *Corresponding Author: lgraf@health.nyc.gov
- 12 Running Title: Delays in COVID-19 Diagnosis and Hospitalization
- 13 MeSH Keywords: COVID-19, SARS-CoV-2, Pandemics, Epidemiology, Early diagnosis,
- 14 Treatment outcome, Patient admission, Length of stay

Abstract:

COVID-19 patients diagnosed ≥3 days after symptom onset had increased odds of hospitalization. The 75th percentile for diagnosis delay was 5 days for residents of low-privilege areas and Black and Hispanic people diagnosed before SARS-CoV-2 Delta predominance, compared with 4 days for other patients, indicating inequities in prompt diagnosis.

Delays in testing or care-seeking for certain respiratory infections can impede access to potentially life-saving treatments (1, 2), contributing to worse outcomes, including hospitalization and death (3). Reasons for delayed care-seeking include prohibitive costs, lack of access to healthcare services, and stigmatization (4, 5). However, little is known about the impact of care-seeking delays on COVID-19 outcomes in the United States (6, 7). We assessed relationships between delays in diagnosis of and hospitalization with COVID-19 and severe outcomes.

The Study

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

The study population included NYC residents symptomatic with COVID-19-like illness and diagnosed with COVID-19 via a positive SARS-CoV-2 molecular or antigen test or hospitalized after exposure to a confirmed COVID-19 case during October 1, 2020–November 30, 2021. We hypothesized that increased time between symptom onset and diagnosis or hospitalization was associated with worse outcomes; accordingly, our exposures were time to diagnosis (days from symptom onset to diagnosis) and time to hospitalization (days from symptom onset to hospital admission), each classified into quintiles. COVID-19 symptoms and symptom onset date were collected through case investigation. Diagnosis date was defined as the earlier of specimen collection date of the first positive test or hospital admission date. Patients with an onset date following their diagnosis or admission date were excluded, effectively excluding healthcare-associated cases. Patients with a diagnosis or admission date >21 days after onset were excluded because true long delays could not be distinguished from data entry errors. Our outcomes of interest were hospitalization, death, and length of hospital stay. A COVID-19 hospitalization was defined as a hospital admission +/- 14 days from a positive SARS-CoV-2 molecular or antigen test or hospitalization at the time of death from COVID-19. A COVID-19

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

death was defined as 1) occurring within +/- 30 days of a positive COVID-19 molecular test and not from external causes or 2) a cause of death of COVID-19 on the death certificate and a positive COVID-19 molecular test. Length of stay was defined as the number of days from hospital admission to discharge and was dichotomized at the median (>5 vs. ≤5 days) (Appendix: Statistical Analysis). The NYC Department of Health and Mental Hygiene's Institutional Review Board determined this work was exempt human subjects research for which consent was not required. Of 864,880 COVID-19 cases diagnosed during October 1, 2020–November 31, 2021, 454,010 patients and 26,462 hospitalized patients were eligible for analysis (Figure 1). Relative to patients diagnosed one day after symptom onset and adjusting for sociodemographic confounders, patients diagnosed the same day as symptom onset (adjusted odds ratio [aOR]: 1.31; 95% confidence interval [CI], 1.25, 1.37), 3–4 days after symptom onset (aOR: 1.08; 95% CI, 1.03, 1.13), and 5–21 days after symptom onset (aOR: 1.36; 95% CI, 1.31, 1.42) had increased odds of hospitalization (Table 1). Patients diagnosed the same day as their symptom onset also had higher odds of death (aOR: 1.21; 95% CI, 1.06, 1.38) (Table 1). Among hospitalized patients, those hospitalized 11–21 days after symptom onset had decreased odds of death compared with patients hospitalized 0–2 days after symptom onset (aOR: 0.73; 95% CI, 0.63, 0.83) (Table 2). Patients hospitalized 6–7 days after symptom onset had increased risk of hospital stay lasting >5 days (adjusted relative risk: 1.09; 95% CI, 1.04, 1.14) (Table 2). For patients diagnosed or hospitalized 1–5 days after symptom onset, diagnosis or hospitalization during a monoclonal (mAb) antibody availability period (January 16– November 30, 2021) relative to a prior period (October 1–December 15, 2020) was not associated with improved outcomes (Appendix: Monoclonal Antibody Availability).

We assessed whether delays from symptom onset to diagnosis varied by race/ethnicity and privilege measured by Index of Concentration at the Extremes (ICE) (8). Early in the study period and before Delta variant predominance (October 2020–June 2021), Black and Hispanic patients and patients in the two lowest quintiles of privilege had longer 75th percentiles for time to COVID-19 diagnosis (5 days) compared with other patients (4 days) (Figure 2). Later in the study period and during Delta variant predominance (July–November 2021), delay distributions were the same for patients of all race/ethnicities and patients in the lowest four quintiles of privilege. Among patients residing in the most privileged census tracts, the 75th percentile of time to diagnosis decreased from 4 days to 3 days (Figure 2).

Conclusions:

Delayed COVID-19 diagnosis ≥ 3 days after symptom onset was associated with increased odds of hospitalization, and hospitalization 6–7 days following symptom onset was associated with longer hospital stays, suggesting delayed testing or care-seeking might contribute to more severe outcomes. Early COVID-19 testing and diagnosis can ensure timely treatment with appropriate therapies including mAb, antivirals, and steroids, which can improve prognosis (9, 10). While we do not have treatment data, our findings are consistent with previous studies that support early diagnosis and hospitalization of COVID-19 patients to prevent severe outcomes (1, 11).

Risk of longer hospital stay was highest for patients hospitalized 6–7 days after symptom onset, consistent with the period when COVID-19 disease severity often increases (12).

Conversely, risk of longer hospital stay and odds of death were decreased in patients hospitalized 11–21 days after symptom onset, perhaps indicating high-risk patients sought care earlier.

Patients diagnosed the same day as symptom onset had greater odds of both hospitalization and

death, potentially reflecting misclassification where patients were misreported as having symptom onset on their diagnosis or admission date despite earlier symptom onset.

Black and Hispanic people and residents of low-privilege areas diagnosed before Delta variant predominance experienced longer times to diagnosis, reflecting systemic racism manifested through reduced access to testing and failure of healthcare systems to build trust (13, 14). In late 2020, NYC Test and Trace Corps deployed mobile testing units and patient navigators to improve testing access in Task Force on Racial Inclusion and Equity (TRIE) neighborhoods, selected based on health status, social inequities, living conditions, occupation, and COVID-19 burden during wave 1 (15). The decrease in time to diagnosis among Black and Hispanic people and residents of the least privileged census tracts over the study period might reflect these targeted efforts to reduce testing inequities. Nevertheless, a decreased time to diagnosis was also observed among patients residing in the most privileged census tracts, indicating persistent inequities in COVID-19 testing access and resources. Sustained funding is necessary to ensure equitable access to testing and care across all communities.

Our analysis has several limitations. First, we did not have data on symptom severity and timing, which limited our ability to distinguish delays in care-seeking from slower illness progression. Second, a portion of patients with symptom onset and diagnosis on the same day could reflect recall bias or data entry errors during case investigations. Third, hospitalizations were ascertained by matching to data sources including hospital databases and health information exchanges and may be incomplete or reflect hospitalizations where SARS-CoV-2 infection was an incidental diagnosis. Nevertheless, our study adds to the limited evidence on outcomes of delays in COVID-19 care-seeking. Future studies should examine the causes of care-seeking delays and inequities to inform messaging and illuminate opportunities to direct testing and

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

resources. In addition to vaccination, early care-seeking will be important in preventing severe COVID-19 outcomes, especially as novel therapeutics emerge. **Acknowledgements:** The authors thank Mary Foote, MD for her guidance and all NYC Department of Health and Mental Hygiene staff activated for the COVID-19 emergency response. **Funding:** The authors received no specific funding for this work beyond their usual salaries. SKG was supported by the Public Health Emergency Preparedness Cooperative Agreement (grant No. NU90TP922035-03-03), funded by the US Centers for Disease Control and Prevention (CDC). **Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. **Biographical Sketch:** Laura E. Graf is a surveillance analyst in the Bureau of Hepatitis, HIV, and Sexually Transmitted Infections at the New York City Department of Health and Mental Hygiene, Queens, New York. Her interests include infectious disease epidemiology and surveillance.

References

131

- 132 1. Alaa A, Qian Z, Rashbass J, Benger J, van der Schaar M. Retrospective cohort study of
- admission timing and mortality following COVID-19 infection in England. BMJ Open. 2020
- 134 Nov 23;10(11):e042712.
- 135 2. Weissman JS, Stern R, Fielding SL, Epstein AM. Delayed access to health care: risk
- factors, reasons, and consequences. Annals of internal medicine. 1991 Feb 15;114(4):325-31.
- 137 3. Ahmed AE. Diagnostic delays in Middle East respiratory syndrome coronavirus patients
- and health systems. J Infect Public Health. 2019 Nov Dec;12(6):767-71.
- 139 4. Pujolar G, Oliver-Angles A, Vargas I, Vazquez ML. Changes in Access to Health
- 140 Services during the COVID-19 Pandemic: A Scoping Review. Int J Environ Res Public Health.
- 141 2022 Feb 3;19(3).
- 142 5. National Center for Health Statistics. Percentage of adults aged 18 and over who delayed
- 143 getting medical care due to cost in past 12 months, United States, 2019—2020. [cited 2022
- 144 February 24]; Available from:
- https://wwwn.cdc.gov/NHISDataQueryTool/SHS_adult/index.html.
- 146 6. Zheng W, Kampfen F, Huang Z. Health-seeking and diagnosis delay and its associated
- factors: a case study on COVID-19 infections in Shaanxi Province, China. Sci Rep. 2021 Aug
- 148 30;11(1):17331.
- 149 7. Muhrer JC. Risk of misdiagnosis and delayed diagnosis with COVID-19: A Syndemic
- 150 Approach. Nurse Pract. 2021 Feb 1;46(2):44-9.
- 151 8. Krieger N, Waterman PD, Spasojevic J, Li W, Maduro G, Van Wye G. Public Health
- Monitoring of Privilege and Deprivation With the Index of Concentration at the Extremes. Am J
- 153 Public Health. 2016 Feb;106(2):256-63.

- Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment contributes to
- alleviate the severity and improve the prognosis of patients with novel coronavirus disease
- 156 (COVID-19). J Intern Med. 2020 Jul;288(1):128-38.
- 157 10. Kow CS, Ramachandram DS, Hasan SS. The use of neutralizing monoclonal antibodies
- and risk of hospital admission and mortality in patients with COVID-19: a systematic review and
- meta-analysis of randomized trials. Immunopharmacol Immunotoxicol. 2022 Feb;44(1):28-34.
- 160 11. Gamboa-Cardenas RV, Barzola-Cerron S, Toledo-Neira D, Reategui-Sokolova C,
- Pimentel-Quiroz V, Zevallos-Miranda F, et al. Predictors of hospitalization for COVID-19 in
- patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clin
- 163 Rheumatol. 2021 Nov;40(11):4725-34.
- 164 12. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
- Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
- 166 JAMA. 2020 Mar 17;323(11):1061-9.
- 167 13. Egede LE, Walker RJ. Structural Racism, Social Risk Factors, and Covid-19 A
- 168 Dangerous Convergence for Black Americans. New England Journal of Medicine.
- 169 2020;383(12):e77.
- 170 14. Ahmed A, Song Y, Wadhera RK. Racial/Ethnic Disparities in Delaying or Not Receiving
- 171 Medical Care During the COVID-19 Pandemic. J Gen Intern Med. 2022 Apr;37(5):1341-3.
- 172 15. Jimenez J, Parra YJ, Murphy K, Chen AN, Cook A, Watkins J, et al. Community-
- 173 Informed Mobile COVID-19 Testing Model to Addressing Health Inequities. J Public Health
- 174 Manag Pract. 2022 Jan-Feb 01;28(Suppl 1):S101-S10.

Table 1. Days from COVID-19 symptom onset to diagnosis and odds of hospitalization and death, New York City, NY, USA, October 2020–November 2021

	Total	Hospitalizations	Days t	o diagnosis and o	odds of hospitalizatio	n	
Days to diagnosis quintile	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR* (95% CI)	p value	
Q1: 0	77,969 (17.2%)	4,967 (19.4%)	1.50 (1.44, 1.57)	<.0001	1.31 (1.25,1.37)	<.0001	
Q2: 1	93,843 (20.7%)	4,071 (15.9%)	REF		REF		
Q3: 2	80,728 (17.8%)	3,588 (14.0%)	1.03 (0.98, 1.07)	0.28	0.96 (0.92,1.01)	0.0867	
Q4: 3-4	99,128 (21.8%)	5,305 (20.7%)	1.25 (1.20, 1.30)	<.0001	1.08 (1.03, 1.13)	0.0007	
Q5: 5-21	102,342 (22.5%)	7,707 (30.0%)	1.80 (1.73, 1.87)	<.0001	1.36 (1.31, 1.42)	<.0001	
		Deaths	Days to diagnosis and odds of death				
		No. (%)	OR (95% CI)	<i>p</i> value	aOR* (95% CI)	p value	
Q1: 0		550 (20.6%)	1.60 (1.41, 1.82)	<.0001	1.21 (1.06, 1.38)	0.0047	
Q2: 1		415 (15.5%)	REF		REF		
Q3: 2		354 (13.2%)	0.99 (0.86, 1.14)	0.90	0.90 (0.77, 1.03)	0.1301	
Q4: 3-4		558 (20.8%)	1.28 (1.12, 1.45)	0.0002	1.01 (0.89, 1.15)	0.8742	
Q5: 5-21						0.1019	

^{*}Adjusted for age group, gender, borough of residence, and neighborhood poverty

Table 2. Days from COVID-19 symptom onset to hospitalization and odds of death and risk of length of stay >5 days*, New York City, NY, USA, October 2020-November 2021

	Total	Deaths	Days to hospitalizat	ion and odds of	death	
Days to hospitalization quintile	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	<i>p</i> value
Q1: 0-2	5,983 (22.6%)	638 (25.8%)	REF		REF	
Q2: 3-5	5,167 (19.5%)	542 (21.9%)	0.98 (0.87, 1.11)	0.77	1.04 (0.91, 1.18)	0.5819
Q3: 6-7	3,973 (15.0%)	390 (15.8%)	0.91 (0.80, 1.04)	0.17	1.03 (0.90, 1.19)	0.6368
Q4: 8-10	5,943 (22.5%)	495 (20.0%)	0.76 (0.67, 0.86)	<.0001	0.90 (0.80, 1.03)	0.1220
Q5: 11-21	5,396 (20.4%)	410 (16.6%)	0.69 (0.61, 0.79)	<.0001	0.73 (0.63, 0.83)	<.0001
		LOS [‡] >5 days	Days to hospitalizat	ion and risk of L	OS [‡] >5 days	
		No. (%)	RR (95% CI)	<i>p</i> value	aRR [†] (95% CI)	p value
Q1: 0-2	4,632 (22.1%)	2,160 (22.3%)	REF		REF	
Q2: 3-5	4,037 (19.2%)	1,904 (19.7%)	1.01 (0.97, 1.06)	0.6207	1.01 (0.97, 1.05)	0.6473
Q3: 6-7	3,172 (15.1%)	1,583 (16.3%)	1.07 (1.02, 1.12)	0.0043	1.09 (1.04, 1.14)	0.0002
Q4: 8-10	4,827 (23.0%)	2,231 (23.0%)	0.99 (0.95, 1.03)	0.6873	1.03 (0.98, 1.07)	0.2425
Q5: 11-21	4,333 (20.6%)	1,809 (18.7%)	0.90 (0.85, 0.94)	<.0001	0.90 (0.86, 0.94)	<.0001

^{*5} days represents the median length of stay for patients hospitalized with COVID-19 in this sample [†]Adjusted for age group, gender, borough of residence, and neighborhood poverty [‡]Length of stay

Appendix, Delays in COVID-19 Diagnosis and Hospitalization and Outcomes — New York

City, New York, USA, October 2020–November 2021

Statistical Analysis

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

Logistic regression was used to assess associations between time to diagnosis and hospitalization or death. Associations between time to hospitalization and length of stay were modeled using log-binomial regression as the outcome of length of stay >5 days was not rare (1). All models were adjusted for age group (<5, 5–14, 15–24, 25–44, 45–64, and \ge 65 years-old), gender, borough of residence, and neighborhood poverty based on census tract per the American Community Survey 2015–2019 as these covariates are known to be associated with both outcome and exposure (2-4). Race/ethnicity was initially considered as an additional confounder but was excluded as a covariate from final models because of high missingness (13.0%). To assess variation in diagnosis delays, we stratified the time between symptom onset and diagnosis by race/ethnicity and privilege measured by Index of Concentration at the Extremes (ICE) (5). ICE was based on patient census tract of residence and categorized into quintiles from least privileged (highest prevalence of low-income (<\$25,000), people of color households) to most privileged (highest prevalence of high-income (\geq \\$100,000), non-Hispanic white households), per the American Community Survey 2015–2019. Of 454,010 patients in the analytical dataset, 59,151 (13.0%) had missing race/ethnicity, and 56 (0.01%) were missing a census tract and could not be assigned an ICE quintile. Data were frozen on April 5, 2022, allowing 4 months for ascertainment of hospitalizations and deaths for patients diagnosed through the end of the study period, November 30, 2021. Only patients diagnosed starting October 1, 2020 were included, as this is when symptom onset date became reliable through case investigation. Prior to October 1, 2020, if

symptom onset date was missing, it was populated by the first positive test date, and we did not want to conflate these two dates. Statistical analyses were performed using SAS Enterprise Guide, version 7.1 (SAS Institute).

Monoclonal Antibody Availability

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

We further explored associations between the exposures of time to diagnosis and time to hospitalization with the outcomes of hospitalization and of death relative to monoclonal antibody (mAb) therapy availability in NYC. Patients were classified into either the pre-mAb period or the mAb availability period. Patient-level mAb data was not available, so mAb availability was considered a proxy of mAb use. mAb therapy availability in NYC increased exponentially between the weeks of December 16, 2020 and January 13, 2021 before reaching a high plateau of approximately 700 mAb treatments administered per week. mAb use decreased as cases decreased between May–July 2021, before increasing to a peak of approximately 2,000 mAb treatments administered per week during the SARS-CoV-2 Delta variant wave (New York City Department of Health and Mental Hygiene, unpub. data). Accordingly, we defined the pre-mAb therapy availability period as October 1, 2020–December 15, 2020 and the mAb availability period as January 16, 2021–November 30, 2021. Patients diagnosed during December 16, 2020– January 15, 2021 were excluded to account for delays in the rollout of mAb therapy. Only patients with a time to diagnosis of 1–5 days were included as the CDC recommends monoclonal antibodies be administered within 10 days of symptom onset, and a secondary analysis that included patients with a time to diagnosis ≤10 days yielded insignificant estimates of the odds of hospitalization and death for patients with a time to diagnosis or hospitalization >5 days. 253,926 patients met the criteria for inclusion in the mAb availability analysis. Compared with patients diagnosed 1–5 days after symptom onset in the pre-mAb availability period, odds

of hospitalization were increased for patients diagnosed during the mAb availability period (aOR: 1.09, 95% CI, 1.04, 1.15). Odds of death were increased during the mAb availability period relative to the pre-mAb availability period among patients hospitalized (aOR: 1.42, 95% CI, 1.12, 1.79), but not diagnosed (aOR: 1.15, 95% CI, 0.98, 1.34), 1–5 days after symptom onset (Appendix Table).

These results contradicted our hypothesis that patients diagnosed during the mAb availability period would have decreased odds of hospitalization and death. This discrepancy could be attributed to our lack of patient-level data on mAb treatment, so diagnosis and hospitalization during the mAb availability period may not reflect mAb use. Also, more severe SARS-CoV-2 variants, including the Delta variant, emerged during the mAb availability period (6). The circulation of these variants may have resulted in increased odds of hospitalization and death in this population even with the availability of mAb. Future studies should include patient-level mAb treatment information.

References

234

- 235 1. Skov T, Deddens J, Petersen MR, Endahl L. Prevalence proportion ratios: estimation and
- 236 hypothesis testing. Int J Epidemiol. 1998 Feb;27(1):91-5.
- 237 2. Muhrer JC. Risk of misdiagnosis and delayed diagnosis with COVID-19: A Syndemic
- 238 Approach. Nurse Pract. 2021 Feb 1;46(2):44-9.
- 3. Gupta S, Hayek SS, Wang W, Chan L, Mathews KS, Melamed ML, et al. Factors
- Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US.
- 241 JAMA Intern Med. 2020 Nov 1;180(11):1436-47.
- 242 4. Zheng W, Kampfen F, Huang Z. Health-seeking and diagnosis delay and its associated
- factors: a case study on COVID-19 infections in Shaanxi Province, China. Sci Rep. 2021 Aug
- 244 30;11(1):17331.
- 5. Krieger N, Waterman PD, Spasojevic J, Li W, Maduro G, Van Wye G. Public Health
- 246 Monitoring of Privilege and Deprivation With the Index of Concentration at the Extremes. Am J
- 247 Public Health. 2016 Feb;106(2):256-63.
- 248 6. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al.
- 249 Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2)
- compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infect Dis. 2022
- 251 Jan;22(1):35-42.


Appendix Table. Days from symptom onset to diagnosis and hospitalization and odds of hospitalization and death by monoclonal antibody

		Total	Days to diagnosis and	Days to diagnosis and odds of hospitalization by mAb* availability			
	mAb						
Days to diagnosis	availabilty	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	<i>p</i> value
1 to 5	No	40,318 (15.9%)	1,948 (15.8%)	REF		REF	
1100	110	+0,510 (15.570)	1,540 (15.070)	IVEI		INLI	
1 to 5	Yes	213,608 (84.1%)	10,415 (84.2%)	1.01 (0.96, 1.06)	0.7063	1.09 (1.04, 1.15)	0.0009
				·			
			Deaths	Days to diagnosis and odds of death by mAb availability			
	mAb			, ,			
Days to diagnosis	availabilty		No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	p value
41.5	NI-		404 (45 50()	DEE		DEE	•
1 to 5	No		194 (15.5%)	REF		REF	
1 to 5	Yes		1,059 (84.5%)	1.03 (0.88, 1.20)	0.7042	1.15 (0.98, 1.34)	0.0787
			,	, , ,		, ,	
		Total	Deaths	Days to hospitalizatio	n and odds o	f death by mAb availab	oility
Days to	mAb			,		1	
hospitalization	availabilty	No. (%)	No. (%)	OR (95% CI)	<i>p</i> value	aOR [†] (95% CI)	p value
41.5	NI-	4.070 (4.4.00()	00 (40 00()	DEE	•	DEE	•
1 to 5	No	1,072 (14.6%)	92 (12.0%)	REF		REF	
1 to 5	Yes	6,278 (85.4%)	672 (88.0%)	1.28 (1.02, 1.60)	0.0359	1.42 (1.12, 1.79)	0.0039
· ·- •		=,=. 0 (000)	(00.070)	5 (5_,55)	0.0000	(,)	0.0000

therapy availability, New York City, NY, USA, October 2020-November 2021

 $^{^{\}star}$ monoclonal antibody † Adjusted for age group, gender, borough of residence, and neighborhood poverty


Figure 1. Flowchart of inclusion in analyses of delays in COVID-19 diagnosis and hospitalization, New York City, NY, USA, October 2020-November 2021



^{*}New York City Office of Chief Medical Examiner

[†]Age group, gender, borough of residence, and neighborhood poverty

Figure 2. Boxplots* of delays from COVID-19 symptom onset to diagnosis by Index of Concentration at the Extremes and race/ethnicity by timing of diagnosis relative to SARS-CoV-2 Delta variant predominance,† New York City, NY, USA, October 2020–November 2021



^{*}The middle line in each box represents the median time to diagnosis. The span of each box is the interquartile range (IQR), from the 25th percentile of time to diagnosis to the 75th percentile. The bottom whisker is the minimum value of time to diagnosis, and the top whisker is 1.5 times the IQR. Patients with time to diagnosis <0 days or >21 days were excluded.

†Delta variant predominance = No defined as diagnosis during October 1, 2020–June 30, 2021. Delta variant predominance = Yes defined as diagnosis during July 1, 2021–November 30, 2021.